Clinical characteristics of 40 patients with early transformation vs 86 patients without transformation or progression for at least 5 years
. | Transformed <5 y . | Not transformed >5 y . | . | ||
---|---|---|---|---|---|
. | (No.) . | (%) . | (No.) . | (%) . | P* . |
Age | |||||
≤60 | 20 | 50 | 49 | 57 | .56 |
>60 | 20 | 50 | 37 | 43 | |
Gender | |||||
Female | 17 | 43 | 42 | 49 | .57 |
Male | 23 | 58 | 44 | 51 | |
B symptoms | |||||
Absent | 35 | 90 | 73 | 87 | .77 |
Present | 4 | 10 | 11 | 13 | |
N/A | 1 | — | 2 | — | |
ECOG | |||||
0-1 | 36 | 95 | 78 | 96 | .65 |
2-4 | 2 | 5 | 3 | 4 | |
N/A | 2 | — | 5 | — | |
Stage | |||||
I-II | 11 | 28 | 20 | 23 | .66 |
III-IV | 28 | 72 | 66 | 77 | |
N/A | 1 | — | 0 | — | |
Extranodal sites | |||||
0-1 | 38 | 95 | 77 | 90 | .50 |
≥1 | 2 | 5 | 9 | 10 | |
Nodal areas | |||||
≤4 | 15 | 56 | 35 | 47 | .50 |
>4 | 12 | 44 | 40 | 53 | |
N/A | 13 | — | 11 | — | |
Tumor mass | |||||
<7 cm | 26 | 81 | 60 | 73 | .47 |
≥7 cm | 6 | 19 | 22 | 27 | |
N/A | 8 | — | 4 | — | |
LDH | |||||
≤ ULN | 24 | 77 | 76 | 95 | .01 |
> ULN | 7 | 23 | 4 | 5 | |
N/A | 9 | — | 6 | — | |
Hemoglobin | |||||
<12 g/dL | 5 | 16 | 4 | 5 | .11 |
≥12 g/dL | 27 | 84 | 80 | 95 | |
N/A | 8 | — | 2 | — | |
FLIPI | |||||
Low/intermediate | 21 | 70 | 59 | 78 | .46 |
High | 9 | 30 | 17 | 22 | |
N/A | 10 | — | 10 | — | |
Primary treatment of stage III/IV | |||||
Observation or local treatment | 15 | 54 | 26 | 39 | .26 |
Systemic treatment | 13 | 46 | 40 | 61 |
. | Transformed <5 y . | Not transformed >5 y . | . | ||
---|---|---|---|---|---|
. | (No.) . | (%) . | (No.) . | (%) . | P* . |
Age | |||||
≤60 | 20 | 50 | 49 | 57 | .56 |
>60 | 20 | 50 | 37 | 43 | |
Gender | |||||
Female | 17 | 43 | 42 | 49 | .57 |
Male | 23 | 58 | 44 | 51 | |
B symptoms | |||||
Absent | 35 | 90 | 73 | 87 | .77 |
Present | 4 | 10 | 11 | 13 | |
N/A | 1 | — | 2 | — | |
ECOG | |||||
0-1 | 36 | 95 | 78 | 96 | .65 |
2-4 | 2 | 5 | 3 | 4 | |
N/A | 2 | — | 5 | — | |
Stage | |||||
I-II | 11 | 28 | 20 | 23 | .66 |
III-IV | 28 | 72 | 66 | 77 | |
N/A | 1 | — | 0 | — | |
Extranodal sites | |||||
0-1 | 38 | 95 | 77 | 90 | .50 |
≥1 | 2 | 5 | 9 | 10 | |
Nodal areas | |||||
≤4 | 15 | 56 | 35 | 47 | .50 |
>4 | 12 | 44 | 40 | 53 | |
N/A | 13 | — | 11 | — | |
Tumor mass | |||||
<7 cm | 26 | 81 | 60 | 73 | .47 |
≥7 cm | 6 | 19 | 22 | 27 | |
N/A | 8 | — | 4 | — | |
LDH | |||||
≤ ULN | 24 | 77 | 76 | 95 | .01 |
> ULN | 7 | 23 | 4 | 5 | |
N/A | 9 | — | 6 | — | |
Hemoglobin | |||||
<12 g/dL | 5 | 16 | 4 | 5 | .11 |
≥12 g/dL | 27 | 84 | 80 | 95 | |
N/A | 8 | — | 2 | — | |
FLIPI | |||||
Low/intermediate | 21 | 70 | 59 | 78 | .46 |
High | 9 | 30 | 17 | 22 | |
N/A | 10 | — | 10 | — | |
Primary treatment of stage III/IV | |||||
Observation or local treatment | 15 | 54 | 26 | 39 | .26 |
Systemic treatment | 13 | 46 | 40 | 61 |
ECOG, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; N/A, not available; ULN, upper limit of normal.
N/A cases were excluded for contingency analyses.